Patent ID: 8148377

Claim:
A method of providing rapid treatment of migraine while minimizing drug-induced side effects, said method comprising: administering a total dose of dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human suffering from migraine via pulmonary administration by oral inhalation, wherein the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof is administered at a rate that provides a mean peak plasma concentration (C max ) of dihydroergotamine of less than 20,000 pg/ml within a mean time to C max (T max ) that is less than 20 minutes after administration, and further wherein the total dose of dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof that is administered ranges from 0.1 to 10 mg per migraine.